First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) Stock Short Interest Falls 50.2%

First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) saw a large decline in short interest in the month of September. As of September 30th, there was short interest totaling 9,470 shares, a decline of 50.2% from the September 15th total of 19,031 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 468,724 shares, the short-interest ratio is currently 0.0 days.

First Trust Nasdaq Pharmaceuticals ETF Price Performance

FTXH stock traded up $0.68 during mid-day trading on Thursday, reaching $41.97. The company had a trading volume of 60,615 shares, compared to its average volume of 232,637. The company has a market capitalization of $1.08 billion, a PE ratio of 14.51 and a beta of 0.45. The firm has a 50 day moving average of $41.11 and a 200 day moving average of $37.75. First Trust Nasdaq Pharmaceuticals ETF has a 12 month low of $28.85 and a 12 month high of $43.52.

First Trust Nasdaq Pharmaceuticals ETF Cuts Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Thursday, September 24th were issued a $0.0113 dividend. The ex-dividend date was Thursday, September 24th. This is a negative change from First Trust Nasdaq Pharmaceuticals ETF’s previous quarterly dividend of $0.0920. This represents a $0.05 dividend on an annualized basis and a dividend yield of 0.1%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Trust Co. of Oklahoma purchased a new position in First Trust Nasdaq Pharmaceuticals ETF during the 3rd quarter worth $1,283,000. MinichMacGregor Wealth Management LLC purchased a new stake in shares of First Trust Nasdaq Pharmaceuticals ETF in the 3rd quarter worth $968,000. Vivaldi Capital Management LP lifted its holdings in shares of First Trust Nasdaq Pharmaceuticals ETF by 16.0% in the 1st quarter. Vivaldi Capital Management LP now owns 12,590 shares of the company’s stock worth $433,000 after buying an additional 1,741 shares during the period. Nilsine Partners LLC lifted its holdings in shares of First Trust Nasdaq Pharmaceuticals ETF by 3.5% in the 2nd quarter. Nilsine Partners LLC now owns 28,057 shares of the company’s stock worth $1,071,000 after buying an additional 937 shares during the period. Finally, Compass Financial Management LLC bought a new position in shares of First Trust Nasdaq Pharmaceuticals ETF during the 2nd quarter worth $29,000.

About First Trust Nasdaq Pharmaceuticals ETF

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.